ExeGi Pharma LLC announced positive topline results from the Phase 1b portion of its PROF study, demonstrating the safety and efficacy of EXE-346 in reducing excessive stool frequency and nighttime awakenings in patients with ileal pouch-anal anastomosis.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.